Abstract
As cardiovascular diseases remain the leading cause of mortality worldwide, a large number of clinical trials are under development, investigating the safety and efficacy of RNA therapeutics in clinical conditions. Nanomedicine based drug delivery systems are currently the new avenue for the treatment of CVDs, providing great advantages to the treatment regime of CVDs. Currently, antisense therapy DNA- and RNA-based and microRNAs are widely applied therapeutic strategies to regulate gene expression and its effect on CVDs. In this review, different biological-based targeting therapies for cardiovascular diseases and their outcomes are discussed.
Keywords: DNA, miRNA, Nanomedicine, Nanoparticles, RNA interference, siRNA.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Drug Targets - Cardiovascular & Hematological Disorders
Current Medicinal Chemistry - Cardiovascular & Hematological Agents
Current Cardiology Reviews
Current Hypertension Reviews
Cardiovascular & Hematological Agents in Medicinal Chemistry
Cardiovascular & Hematological Disorders-Drug Targets
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents